Subtype
Primary Central Nervous System Neoplasm
CI-CAN-00001432Explore in graph →
Non-malignant957 active trials5 approved drugs175 evidence items
- NCIt
- C102871
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001432Explore in graph →
Clinical trials
3,294 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06519682 | A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG) | recruiting | N/A | 20 | Daniel MorgensternOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04863950 | Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma | recruiting | Phase 2 | 25 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Aug 27, 2025 |
| clinicaltrials |
| NCT07144735 | Allogeneic γδT Cells in Glioblastoma(ABOUT) | recruiting | N/A | 18 | Peking University Third HospitalOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT04587830 | ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme(GBM) | active not recruiting | Phase 2 | 100 | Polaris GroupINDUSTRY | 2 | Aug 26, 2025 | clinicaltrials |
| NCT07138001 | Phase 2 Clinical Trial of KH617 | not yet recruiting | Phase 2 | 60 | Sichuan Honghe Biotechnology Co., Ltd.INDUSTRY | 0 | Aug 22, 2025 | clinicaltrials |
| NCT04747145 | Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma | active not recruiting | Phase 2 | 38 | Medical College of WisconsinOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT04910022 | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 150 | Nerviano Medical SciencesINDUSTRY | 5 | Aug 19, 2025 | clinicaltrials |
| NCT06018363 | Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection | recruiting | Phase 1 / Phase 2 | 25 | Dushu Lake Hospital Affiliated to Soochow UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07130149 | Sonodynamic-Chemoradiotherapy Integration in Glioblastoma | enrolling by invitation | Phase 2 | 230 | Yingjuan ZhengOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05222802 | A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) | active not recruiting | Phase 1 | 52 | Katmai Pharmaceuticals Inc.INDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06385132 | Psychological and Psychiatric prOfile in Glioblastoma and Head and Neck Cancer(APPOINT) | recruiting | — | 207 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07121842 | Glioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI(GLIMPCE) | recruiting | N/A | 120 | Erasmus Medical CenterOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07119294 | Molecular Imaging of Cancer-associated Fibroblasts in Glioblastoma: a FAPI PET/MR Study.(GlioFAPI) | recruiting | N/A | 50 | Jules Bordet InstituteOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07120984 | A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma(IMAGLIO) | not yet recruiting | Phase 2 | 52 | Philogen S.p.A.INDUSTRY | 0 | Aug 13, 2025 | clinicaltrials |
| NCT03672721 | IA Carboplatin + Radiotherapy in Relapsing GBM | recruiting | Phase 1 / Phase 2 | 35 | Université de SherbrookeOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05970757 | Physiological MRI for Precision Radiotherapy IDH-wildtype Glioblastoma(PhysMRRT) | active not recruiting | N/A | 10 | Erasmus Medical CenterOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06002711 | Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study | recruiting | — | 500 | RenJi HospitalOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT06617208 | Prognostic IntraOperative Biomarkers ideNtification in Tumor rElatEd suRgery(PIONEER) | not yet recruiting | N/A | 10 | Erasmus Medical CenterOTHER | 0 | Aug 8, 2025 | clinicaltrials |
| NCT07111195 | Feasibility of ONCOhabitats for Surgical and Treatment Planning in IDH-Wildtype Glioblastoma (SINUE)(SINUE) | recruiting | — | 140 | Juan M Garcia-GomezOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT06356883 | Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma | recruiting | Phase 2 | 120 | Université de SherbrookeOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07106008 | Radiolabeled TSPO Targeted Molecular Probe in Glioma | not yet recruiting | — | 8 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT07025018 | Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations | recruiting | Phase 1 | 52 | HutchmedINDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT04961515 | Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma | recruiting | Phase 2 | 19 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06430424 | Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma(GBrecurr) | recruiting | — | 40 | University Hospital, BordeauxOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT04175301 | Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas. | active not recruiting | Phase 2 | 15 | Stony Brook UniversityOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06299891 | Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity | recruiting | Phase 2 | 24 | Seattle Children's HospitalOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05929495 | Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma | recruiting | Phase 2 | 25 | University of Milano BicoccaOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04135807 | Implantable Microdevice In Primary Brain Tumors | recruiting | Early Phase 1 | 12 | Oliver JonasOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04523688 | Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma(Combi G-Vax) | recruiting | Phase 2 | 28 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05909618 | Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases(14) | recruiting | Phase 2 | 33 | Sheba Medical CenterOTHER_GOV | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07074470 | Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL(VPX) | recruiting | N/A | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06099743 | ASCENT Intervention for Brain Tumor Patients | recruiting | N/A | 100 | Massachusetts General HospitalOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT03893487 | Fimepinostat in Treating Brain Tumors in Children and Young Adults(PNOC016) | active not recruiting | Early Phase 1 | 30 | Sabine Mueller, MD, PhDOTHER | 2 | Jul 11, 2025 | clinicaltrials |
| NCT04266977 | Restrictive Use of Dexamethasone in Glioblastoma(RESDEX) | recruiting | N/A | 50 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06632860 | A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors | recruiting | Early Phase 1 | 40 | Peking Union Medical College HospitalOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06773481 | BC008-1A Injection for Recurrent CNS WHO G4 Glioma | recruiting | Phase 1 | 40 | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07047066 | A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma | not yet recruiting | Phase 2 | 30 | Tongji HospitalOTHER | 0 | Jul 2, 2025 | clinicaltrials |
| NCT04047706 | Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 | 18 | Northwestern UniversityOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07044076 | Translation and Validation of the MQOL Self-questionnaire Into French for Assessing Quality of Life in Patients With Meningiomas(MenQOL) | recruiting | — | 50 | Centre Hospitalier St AnneOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT02780024 | Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM | active not recruiting | Phase 2 | 50 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04765098 | Tamoxifen Versus Etoposide After First Recurrence in GBM Patients | recruiting | Phase 2 | 60 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06896110 | Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma | enrolling by invitation | Phase 1 | 34 | Andrew P. GrovesOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04121455 | Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients(GLORIA) | active not recruiting | Phase 1 / Phase 2 | 117 | TME Pharma AGINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT05879367 | Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma | recruiting | Phase 1 | 66 | Orbus Therapeutics, Inc.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06036706 | Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:(CANCER-COG) | recruiting | N/A | 108 | Centre Francois BaclesseOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07029100 | Feasibility of ORGAnoids in Routine Clinical Practice for Molecular Analysis of the GLIOvascular Niche in Patients With Primary Brain Tumors.(ORGA-GLIO) | not yet recruiting | N/A | 30 | Centre Henri BecquerelOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT04019262 | Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 2 | John FlickingerOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT06183983 | Hitting the Mark: Introducing State-of-the-art MRI for Precision Radiotherapy of Glioblastoma(MOSAIC) | recruiting | N/A | 53 | Erasmus Medical CenterOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT07014943 | High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 34 | Sichuan UniversityOTHER | 1 | Jun 11, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 29, 2025source: clinicaltrials